SCHEMBL8265702

SCHEMBL8265702

COC(=O)CC(CCI)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
KCNA5 P22460 1/20 0.46
F2 P00734 6/20 0.45
F10 P00742 5/20 0.45
PRSS1 P07477 4/20 0.44
KMT2A Q03164 1/20 0.43
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42
GABBR2 O75899 1/20 0.41
GABBR1 Q9UBS5 1/20 0.41
HPGD P15428 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7995142 0.86 ALDH1A1 (0.67) ALDH1A1KCNA5KMT2AFNTAFNTB
SCHEMBL1811944 0.85 ALDH1A1 (0.55) ALDH1A1KCNA5F2F10PRSS1
SCHEMBL27323723 0.85 ALDH1A1 (0.55) ALDH1A1KCNA5F2F10PRSS1
SCHEMBL28044957 0.85 ALDH1A1 (0.55) ALDH1A1KCNA5F2F10PRSS1
SCHEMBL13136720 0.84 ALDH1A1 (0.54) ALDH1A1KCNA5F2F10PRSS1
SCHEMBL9424092 0.83 ALDH1A1 (0.52) ALDH1A1KCNA5F2F10PRSS1
SCHEMBL12268202 0.81 ALDH1A1 (0.61) ALDH1A1KCNA5KMT2AFNTAFNTB
SCHEMBL22303151 0.81 ALDH1A1 (0.57) ALDH1A1KCNA5KMT2AGABBR2GABBR1
SCHEMBL1811811 0.81 ALDH1A1 (0.61) ALDH1A1KCNA5KMT2AFNTAFNTB
SCHEMBL7239668 0.81 ALDH1A1 (0.57) ALDH1A1KCNA5KMT2AGABBR2GABBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817312-B1 MACROCYCLIC AMINOPYRIDYL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2011-06-08 EP disclosed
US-7951949-B2 Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2011-05-31 US disclosed
US-20080015213-A1 Macrocyclic Aminopyridyl Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease MERCK SHARP & DOHME LLC 2008-01-17 US disclosed
US-20080015213-A1 Macrocyclic Aminopyridyl Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease MERCK SHARP & DOHME LLC 2008-01-17 US disclosed
WO-2006057983-A1 MACROCYCLIC AMINOPYRIDYL BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015213-A1 Macrocyclic Aminopyridyl Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease BACE1, BACE2, APP ALDH1A1 2705/4885KCNA5 3590/4885F2 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.